India DCGI Urges Cancer Drugs Be Included In Price Cap System
This article was originally published in PharmAsia News
Executive SummaryThe Drug Controller General of India is pushing to have cancer drugs added to the country's system of price caps on pharmaceuticals. DCGI Surinder Singh said cancer drugs have become too expensive for those who need them, partly because five multinational companies have a near monopoly on that drug sector. He said Eli Lilly, GlaxoSmithKline, Pfizer, Roche and Sanofi-Aventis control the cancer category of drugs. Singh said he has recommended inclusion of cancer drugs in the National Pharmaceutical Pricing Authority, but it would be up to the department of pharmaceuticals to do so. (Click here for more
You may also be interested in...
A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.